Advertisement
- United States
- /
- Biotech
- /
- NasdaqGS:ASND
Ascendis Pharma First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Ascendis Pharma (NASDAQ:ASND) First Quarter 2025 Results
Key Financial Results
- Revenue: €101.0m (up 5.3% from 1Q 2024).
- Net loss: €94.6m (loss narrowed by 28% from 1Q 2024).
- €1.58 loss per share (improved from €2.30 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ascendis Pharma Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 3.6% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Ascendis Pharma you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ASND
Ascendis Pharma
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
High growth potential and good value.
Market Insights
Advertisement
Weekly Picks
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3637.3% undervalued
27 followersusers have followed this narrative
14 commentsusers have commented on this narrative
17 likesusers have liked this narrative
MA
Marek_Trnka on CSG ·
Czechoslovak Group - is it really so hot?
Fair Value:€5547.0% undervalued
35 followersusers have followed this narrative
1 commentusers have commented on this narrative
13 likesusers have liked this narrative
AL
alex30free on Swedencare ·
The Compound Effect: From Acquisition to Integration
Fair Value:SEK 46.2846.5% undervalued
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Recently Updated Narratives
RE
RecMag on Proximus ·
Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.
Fair Value:€2567.1% undervalued
37 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
andre_santos on Spotify Technology ·
Spotify - A Fundamental and Historical Valuation
Fair Value:US$357.7624.6% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CO
Coward_Nutlick on Elicio Therapeutics ·
Very Bullish
Fair Value:US$10091.6% undervalued
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.8% undervalued
57 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3319.7% undervalued
79 followersusers have followed this narrative
0 commentsusers have commented on this narrative
20 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0226.1% undervalued
1067 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
Trending Discussion
US
User on Tesla ·
When was the last time that Tesla delivered on its promises? Lets go through the list! The last successful would be the Tesla Model 3 which was 2019 with first deliveries 2017. Roadster not shipped. Tesla Cybertruck global roll out failed. They might have a bunch of prototypes (that are being controlled remotely) And you think they'll be able to ship something as complicated as a robot? It's a pure speculation buy.
3
|1
US
User on Tesla ·
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
2
|0
TI
TickerTickle on Figma ·
Figma is still deeply embedded as the default design system in big companies, and the ecosystem (Buzz, Slides, Sites, Make) is clearly the strategic play rather than a one‑off product bet. None of those qualitative assumptions have really broken yet, the bigger change has been sentiment toward growth/AI software in general, not Figma’s product reality. Assuming ~30% annual growth, margins stepping up to 25%, and a 40x PE in 2030 with an 8.4% discount rate is too optimistic now considering how the broader market is now pricing similar SaaS names, which means you can believe in the long term thesis and still accept that the stock might chop sideways or even drift lower while expectations and multiples reset. I will be sharing an update soon.
1
|0